Celgene Corp (CELG) 115.54 $CELG Final Glance:

New Post Public Reply Private Reply Replies (0) Message Board

Apr 23, 2015 at 12:57 AM

Celgene Corp (CELG) 115.54 $CELG

Final Glance: Biotechnology companies
AP - Wed Apr 22, 5:13PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 104.18 (-1.02), AMGN: 169.10 (+0.64), CELG: 115.54 (+0.72)

An Analysis Of Acceleron, A Development-Stage Celgene Partner
DoctoRx - at Seeking Alpha - Wed Apr 22, 1:58PM CDT

XLRN: 33.67 (-0.02), CELG: 115.54 (+0.72)

Midday Glance: Biotechnology companies
AP - Wed Apr 22, 12:39PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 104.18 (-1.02), AMGN: 169.10 (+0.64), CELG: 115.54 (+0.72)

Early Glance: Biotechnology companies
AP - Wed Apr 22, 9:25AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 104.18 (-1.02), AMGN: 169.10 (+0.64), CELG: 115.54 (+0.72)

Amgen Earnings Reveals Ugly Truth About Drug Pricing and Sales 'Growth'
at The Street - Wed Apr 22, 9:18AM CDT
It's common for drug companies to raise the price of their existing products once or twice per year, every year. The price increases far outpace the rate of inflation.
BIIB: 423.57 (+1.46), GILD: 104.18 (-1.02), AMGN: 169.10 (+0.64), CELG: 115.54 (+0.72)

Critical Alerts For Celgene, Rambus, Mylan, Amgen and Zoetis Released By InvestorsObserver
PR Newswire - Wed Apr 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CELG, RMBS, MYL, AMGN and ZTS.
ZTS: 47.03 (-0.51), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), RMBS: 14.40 (+0.22), CELG: 115.54 (+0.72)

A Discussion Of Amgen's Q1 Results, With Updates On Its Pipeline
DoctoRx - at Seeking Alpha - Wed Apr 22, 8:28AM CDT

PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41), HSP: 87.80 (+0.04), CELG: 115.54 (+0.72)

3 Questions to Ask Before You Buy a Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 21, 12:06PM CDT
Source: Celgene Corporation. The biotech industry is notorious for its pop and drop nature. Biotech stocks can soar or burst based on whims and whispers surrounding clinical trials, FDA approvals, and competitive threats. As a result, picking the...
MNKD: 4.90 (-0.09), CELG: 115.54 (+0.72)

Stock Updates on Biotech -- Celgene, Amgen, PDL BioPharma, Amarin, and Pharmacyclics
PR Newswire - Tue Apr 21, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PCYC: 256.98 (-0.77), AMRN: 2.34 (-0.05), AMGN: 169.10 (+0.64), PDLI: 7.07 (unch), CELG: 115.54 (+0.72), CELGZ: 2.87 (+0.04)

Jim Cramer's 'Mad Money' Recap: How to Become an Even Better Investor
at The Street - Mon Apr 20, 6:00PM CDT
Cramer's first rule: Diversification is the only way to invest.
DUK: 78.30 (+0.23), SVU: 11.01 (-0.10), FB: 84.63 (+1.01), SKT: 34.36 (+0.07), ED: 61.64 (+0.17), FRT: 140.45 (+0.24), RSH: 0.24 (-0.04), PLKI: 56.99 (-0.03), CELG: 115.54 (+0.72), RAD: 8.32 (+0.39), T: 32.86 (+0.20), S: 5.08 (+0.10), CMG: 641.23 (-51.29), GLD: 113.83 (-1.55), GOOGL: 549.18 (+6.26), VZ: 49.57 (+0.40), AAPL: 128.62 (+1.71), REGN: 472.63 (+9.41)

How to Invest Money in Biotech
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 19, 1:02PM CDT
Source: Isis Pharmaceuticals, Facebook. I believe it goes without saying that the biotechnology sector is one of the most unique sectors in the stock market. Whereas most industries (and the companies within those industries) are valued based on...
ISIS: 66.26 (-0.03), GILD: 104.18 (-1.02), XBI: 232.63 (-0.32), CELG: 115.54 (+0.72)

How To Invest In ETFs: Tips To Trade Top Market Trends
at Investor's Business Daily - Fri Apr 17, 7:04PM CDT
ETF trading offers a way to buck the conventional wisdom about investing in stocks and other financial markets. The conventional wisdom says you can't time the stock market. You should remain fully invested through bull and bear markets, and you'll...
BIIB: 423.57 (+1.46), GILD: 104.18 (-1.02), IBB: 363.84 (-0.66), CELG: 115.54 (+0.72)

Seeking Alpha's Biotech Weekly: Celgene Check-Up, Is Gilead The New Apple?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors geared up for earnings season, highlighted several...
SGYP: 4.01 (-0.06), BIIB: 423.57 (+1.46), ARWR: 6.88 (+0.14), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), BMY: 66.60 (-0.21), CNCE: 14.83 (+0.26), CELG: 115.54 (+0.72), ATNM: 3.01 (-0.07), PFS: 18.65 (+0.06), NVIV: 13.76 (-0.19), GILD: 104.18 (-1.02), FWP: 31.77 (-0.66), GWPH: 113.04 (-0.05), IBM: 165.36 (+1.10), BAX: 70.38 (+0.33), AZN: 73.35 (+0.65), TEVA: 63.01 (-1.15)

Celgene: A Pre-Earnings Discussion Based On Recent News
DoctoRx - at Seeking Alpha - Fri Apr 17, 12:01PM CDT

CELG: 115.54 (+0.72)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...